Published in Clin Cancer Res on February 27, 2015
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175
Safety Study of PLX4032 in Patients With Solid Tumors | NCT00405587
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science (2008) 16.60
Classification of papillomaviruses. Virology (2004) 14.16
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A (2008) 4.74
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60
Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst (1990) 3.98
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol (2014) 2.10
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol (2014) 2.03
Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol (2008) 1.96
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol (2003) 1.81
UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer (2002) 1.66
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis (2007) 1.54
Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol (2009) 1.53
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol (2011) 1.46
Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol (1999) 1.46
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol (2012) 1.33
Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol (2012) 1.32
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol (2012) 1.27
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol (2013) 1.20
A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol (2003) 1.17
High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. Int J Cancer (2011) 1.16
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol (2013) 1.12
Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol (2009) 1.06
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife (2013) 1.02
Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol (2015) 0.97
Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol (2012) 0.96
Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev (2014) 0.93
Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation. PLoS One (2010) 0.90
Tumor suppressor gene mutations and photocarcinogenesis. Photochem Photobiol (1996) 0.89
Betapapillomavirus infection profiles in tissue sets from cutaneous squamous cell-carcinoma patients. Int J Cancer (2010) 0.86
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res (2014) 0.85
False-positive polymerase chain reaction results for human papillomavirus in lichen planus. Potential laboratory pitfalls of this procedure. J Am Acad Dermatol (1996) 0.84
Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis (2012) 0.84
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer (2014) 0.83
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res (2012) 0.82
HPV typing in Brazilian patients with epidermodysplasia verruciformis: high prevalence of EV-HPV 25. J Cutan Med Surg (2004) 0.80
Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol (2013) 0.79
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol (2013) 0.79
RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma. J Invest Dermatol (2014) 0.77
Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential. JAMA Dermatol (2014) 0.76
Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: a case series. Br J Dermatol (2014) 0.76